GANX Stock Analysis: Buy, Sell, or Hold?
GANX - Gain Therapeutics, Inc. Common Stock
$2.01
0.02 (1.26%)
â˛
5d:
-5.42%
30d:
+10.16%
90d:
+14.57%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When GANX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: GANX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: GANX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: GANX is currently trading at $2.00, which is considered slightly high relative to its 30-day fair value range of $1.70 to $2.02.
Technical Outlook: Technically, GANX is showing sideways momentum. Immediate support is located at $1.76, while resistance sits at $2.37.
Market Sentiment: GANX scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $7.20 (+259.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GANX is showing sideways momentum. Immediate support is located at $1.76, while resistance sits at $2.37.
Market Sentiment: GANX scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $7.20 (+259.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$1.70 -
$2.02
Company Quality Score
37/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
54.2%
All Signals
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (8/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 259.1% below Wall St target ($7.20)
- WARNING: Composite score 37/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.70 -
$2.02
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
Âą$0.30
(15.2%)
Support & Resistance Levels
Support Level
$1.76
Resistance Level
$2.37
Current Trend
Sideways
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.52
Wall Street Target
$7.20
(+259.1%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: August 24, 2026 8:26 AM ET
Data refreshes hourly during market hours. Next update: 9:26 AM
Data refreshes hourly during market hours. Next update: 9:26 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GANX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$55 | 57 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
RCKT
Rocket Pharmaceuticals IâĻ |
STRONG BUY
18 analysts |
$9 | 53 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$88 | 40 SELL |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$52 | 42 HOLD |
